Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, has raised a $25M Series A — Altis Labs, an AI software company for drug development, raised a $25 million Series A, CEO Felix Baldauf-Lenschen tells Axios Pro.
Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, has raised a $25M Series A — Altis Labs, an AI software company for drug...
Natalie Breymeyer / Axios: Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, has raised a $25M Series A — Altis Labs, an AI...
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, has raised a $25M Series A — Altis Labs, an AI software company for drug development, raised a $25 million Series A, CEO Felix Baldauf-Lenschen tells Axios Pro.
Open the app view to save this story, compare related coverage, and continue from the same source.